-- Avastin: The first presentation of data from Avastin-based therapy with
or without cetuximab (a drug which attacks cancer differently to
Avastin) in patients with metastatic colorectal cancer will be shared.
-- Avastin: Impressive long-term overall survival data at two years,
involving some 4,000 patients treated with Avastin first-line in
combination with a variety of chemotherapy regimens will confirm the
pivotal role that Avastin is now playing in patients with advanced
colorectal cancer. The results of the studies are significant because
over 50 percent of people diagnosed with colorectal cancer currently
die of the disease and these data show that improvements in survival
are achievable. (1)
Roche will present nearly 300 abstracts and posters at ASCO that
demonstrate advances in other major cancers, as well as the data already
described above in breast and colorectal. With one of the most
comprehensive oncology research and development pipelines in the industry,
Roche is striving to deliver even more treatment options in the fight
against cancer. For example, Avastin's clinical trial program includes
40,000 patients worldwide.
Key sessions at which Roche data will be presented include:
Avastin AVADO study. Miles D, et al, Sunday 1 June 2008,
Abstract No. LBA1011, oral 8:30am - 8:45am, E
presentation Hall D1
ASCO press briefing Saturday 31 May
2008, 9:00am, Press
Herceptin HER2-positive metastatic breast Tuesday 3 June 2008,
cancer study. Minckwitz G Von, et 8:00am - 12:00pm,
al, Abstract No. 1025, Poster No.
Copyright©2008 PR Newswire.
All rights reserved